AAPS PharmSciTech

, 10:1071 | Cite as

Formulation and Evaluation of Gastroretentive Drug Delivery System of Propranolol Hydrochloride

  • Swati C. Jagdale
  • Amit J. Agavekar
  • Sudhir V. Pandya
  • Bhanudas S. Kuchekar
  • Aniruddha R. Chabukswar
Research Article


The objective of present study was to develop a gastroretentive drug delivery system of propranolol hydrochloride. The biggest problem in oral drug delivery is low and erratic drug bioavailability. The ability of various polymers to retain the drug when used in different concentrations was investigated. Hydroxypropyl methylcellulose (HPMC) K4 M, HPMC E 15 LV, hydroxypropyl cellulose (HPC; Klucel HF), xanthan gum, and sodium alginate (Keltose) were evaluated for their gel-forming abilities. One of the disadvantages in using propranolol is extensive first pass metabolism of drug and only 25% reaches systemic circulation. The bioavailability of propranolol increases in presence of food. Also, the absorption of various drugs such as propranolol through P-glycoprotein (P-gp) efflux transporter is low and erratic. The density of P-gp increases toward the distal part of the gastrointestinal tract (GIT). Therefore, it was decided to formulate floating tablet of propranolol so that it remains in the upper part of GIT for longer time. They were evaluated for physical properties, in vitro release as well as in vivo behavior. In preliminary trials, tablets formulated with HPC, sodium alginate, and HPMC E 15 LV failed to produce matrix of required strength, whereas formulation containing xanthan gum showed good drug retaining abilities but floating abilities were found to be poor. Finally, floating tablets were formulated with HPMC K4 M and HPC.

Key words

floating delivery gastroretentive hydroxypropyl methylcellulose propranolol hydrochloride 


  1. 1.
    Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235–59. Review.PubMedCrossRefGoogle Scholar
  2. 2.
    Chawla G, Gupta P, Bansal AK. In: Jain NK, editor. Progress in controlled and novel drug delivery. 1st ed. New Delhi: CBS; 2001. p. 76–97.Google Scholar
  3. 3.
    Tripathi KD. Antihypertensive drugs, essentials of medical pharmacology. 5th ed. New Delhi: Jaypee Brothers; 2003. p. 235–6.Google Scholar
  4. 4.
    Woodlinger AM. Cardiovascular drugs. In: Troy DB, editor. Remington the science and practice of pharmacy, Indian edition. 21st ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 1350.Google Scholar
  5. 5.
    Williams DA, Temke TL. Foyes principles of medicinal chemistry, International student edition. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 489–93.Google Scholar
  6. 6.
    Indian Pharmacopoeia. Government of India, Ministry of Health and Family Welfare, vol. II. Delhi: The Controller of Publication; 1996. p. 634.Google Scholar
  7. 7.
    Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):250.CrossRefGoogle Scholar
  8. 8.
    Singh BN, Kim KH. Encyclopedia of pharmaceutical technology, drug delivery: oral route. New York: Marcel Dekker; 2001. p. 1253.Google Scholar
  9. 9.
    Khattar D, Ahuja A, Khar RK. Hydrodynamically balanced systems as sustained release dosage forms for propranolol hydrochloride. Pharmazie. 1990;45(5):356–8.PubMedGoogle Scholar
  10. 10.
    Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using factorial a design. Int J Pharm. 1997;154:49–54.CrossRefGoogle Scholar
  11. 11.
    Narendra C, Srinath MS, Babu G. Optimization of bilayer floating tablet containing metoprolol tartarate as a model drug for gastric retention. AAPS Pharm Sci Tech. 2006;7(2):Article 34.Google Scholar
  12. 12.
    Ali J, Ahuja A, Khar RK, Baboota S. Formulation and development of hydrodynamically balanced system for metformin. Eur J Pharm Biopharm. 2007;67:196–201.PubMedCrossRefGoogle Scholar
  13. 13.
    Basak SC, Rao KN, Manavalan R, Rao PR. Development and in vitro evaluation of floating matrix tablet of ciprofloxacin. Indian J Pharm Sci. 2004;66(3):313–6.Google Scholar
  14. 14.
    Sriamornsak P, Thirawong N, Korkard K. Swelling, erosion and release behavior of alginate-based matrix tablets. Eur. J. Pharm. Biopharm. 2007;66:435–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang YB, Tsai YH, Yang WC, Wu PC, Chang JS. Influence of formulation variables and manufacturing process on propranolol extended release profile from HPMC matrices tablets. J Appl Polymer Sci. 2004;93(4):1886–90.CrossRefGoogle Scholar
  16. 16.
    Huang YB, Tsai YH, Yang WC, Wu PC, Chang JS. Optimization of sustained release propranolol dosage form using factorial design and response surface methodology. Biol Pharm Bull. 2004;27(10):1626–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Garg S, Sharma S. Gastroretentive drug delivery systems. Business briefings. Pharmatech. 2003;162.Google Scholar
  18. 18.
    Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005;6(3):Article 47.Google Scholar
  19. 19.
    Baumgartner S. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int. J. Pharm. 2000;195:125–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Staniforth J. In: Aulton ME, editor. Pharmaceutics: the science of dosage form design. 2nd ed. London: Churchill Livingstone; 2002. p. 207–8.Google Scholar
  21. 21.
    USP NF. The official compendia of standards. The United States Pharmacopoeial Convention. Asian edition. Propranolol extended release capsules. 2006;3115.Google Scholar
  22. 22.
    Costa P, Sousa Lobo JM. Review: modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Gohel MC, Amin AF, Patel KV, Panchal MK. Studies in release behavior of diltiazem HCl from matrix tablets containing (hydroxypropyl) methyl cellulose and xanthan gum. Boll. Chim. Farm. 2002;141:21–8.PubMedGoogle Scholar
  24. 24.
    Gambhire MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR. Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS PharmSciTech. 2007;8(3):Article 73.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Swati C. Jagdale
    • 1
  • Amit J. Agavekar
    • 2
  • Sudhir V. Pandya
    • 3
  • Bhanudas S. Kuchekar
    • 2
  • Aniruddha R. Chabukswar
    • 4
  1. 1.Department of PharmaceuticsMAEER’s Maharashtra Institute of PharmacyPuneIndia
  2. 2.MAEER’s Maharashtra Institute of PharmacyPuneIndia
  3. 3.Quality AssuranceNulife PharmaceuticalsPuneIndia
  4. 4.Department of Pharmaceutical ChemistryMAEER’s Maharashtra Institute of PharmacyPuneIndia

Personalised recommendations